NSC16168 (20 mg/kg, ip, twice daily) exhibits significant anti-tumor activity and potentiates cisplatin antitumor activity in H460 lung cancer xenografts.
< /b>
| Animal Model: | 2.5×10 6 H460 cells were injected sc in the right flank of each mouse.
|
| Dosage: | 20 mg/kg. |
| Administration: | IP, twice daily for 10 days. |
| Result: | The tumor growth was minimally affected by compound and the mice displayed no signs of distress or toxic side effects.
The combination treatment with 16168 and cisplatin inhibited H460 tumor growth, which was maintained for the duration of the compound injections. |
